Physician

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Polyphagia, EUR, Cachexia, Charisma House, Orbit, Therapy, AKT, PWS, Solution, University of Copenhagen Faculty of Health and Medical Sciences, Chronic obstructive pulmonary disease, Novo Nordisk Foundation, BII, Cancer, Patient, Death, Lists of diseases, Physician, Health, Diabetes, AI, Prader–Willi syndrome, DKK, Environment, University, Primate, MVP, Company, Program, Woman, Life, Growth, Fertility, Ovarian follicle, Risk, Science, Burn, Weight gain, Research, Drug development, Obesity, Neptune, Survival, Mark (given name), Inotify, Quality of life, Pharmacotherapy, Rheumatoid arthritis, Chronic kidney disease, Pharmaceutical industry, Risk management, Fine chemical, Medical imaging
Thursday, September 23, 2021 - 8:00am

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Polyphagia, EUR, Cachexia, Charisma House, Orbit, Therapy, AKT, PWS, Solution, University of Copenhagen Faculty of Health and Medical Sciences, Chronic obstructive pulmonary disease, Novo Nordisk Foundation, BII, Cancer, Patient, Death, Lists of diseases, Physician, Health, Diabetes, AI, Prader–Willi syndrome, DKK, Environment, University, Primate, MVP, Company, Program, Woman, Life, Growth, Fertility, Ovarian follicle, Risk, Science, Burn, Weight gain, Research, Drug development, Obesity, Neptune, Survival, Mark (given name), Inotify, Quality of life, Pharmacotherapy, Rheumatoid arthritis, Chronic kidney disease, Health insurance, Pharmaceutical industry, Risk management, Fine chemical, Medical imaging
Thursday, September 23, 2021 - 8:00am

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program. Creation House consists of a founder-friendly convertible loan of DKK 10M and 18 months incubation at BII with access to labs and office space, business development support, and BII partners. The program allows participants to meet and interact with BII's network of investors, industry partners, alumni and fellow entrepreneurs across its other programs, and is specifically designed to guide companies to a competitive international level and prepare teams for discussions with investors ahead of series A financing rounds.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.

Therapy, Probability, Failure, Business architecture, Bone marrow, Degenerative disease, Annual report, Security (finance), U.S. Securities and Exchange Commission, Carma, Patient, Nasdaq, Population, Physician, Lists of diseases, Business, Biology, Private Securities Litigation Reform Act, Industry, Acquisition, Risk, COVID-19, Stem cell, PIPE, Forward-looking statement, Safety, Investment, Metalmark, NEW, SEC, GLOBE, Pharmaceutical industry
Wednesday, September 22, 2021 - 11:38pm

REDWOOD CITY, Calif. and NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC) (“AMHC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business Combination”) with Jasper Therapeutics, Inc. (“Jasper”), a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell, and all other proposals presented at AMHC’’s special shareholder’s meeting held on September 22, 2021.

Key Points: 
  • AMHCs shareholders approved the Business Combination proposal with 74.9% votes in favor of the approximately 9,872,643 AMHC votes cast at the meeting.
  • Holders of 9,262,099 shares of AMHC Class A common stock have elected to redeem their shares in connection with the Business Combination.
  • Subject to the satisfaction or waiver of the other customary closing conditions, the Business Combination is expected to close on or about September 24, 2021.
  • AMHC and Jasper Therapeutics anticipate that subsequent events and developments will cause AMHCs and Jasper Therapeutics assessments to change.

TTUHSC El Paso's Life-Saving Cancer Prevention Programs Receive $5 Million in CPRIT Funding

Mortality, BEST, Breast, Insurance, Colorectal cancer, Texas Panhandle, Public health, Large intestine, Breast cancer, Depression, Patient, Research institute, Physician, Cancer prevention, Texas Tech University Health Sciences Center, Woman, Colorado Water Quality Control Division, Center, Disease, Department, Education, GLOBE, Cancer Prevention and Research Institute of Texas, Health insurance, Birth control
Wednesday, September 22, 2021 - 8:30pm

TTUHSC El Paso's SuCCCeS and the Breast Cancer Education, Screening and Navigation (BEST) programs screen for cancer and provide cancer-prevention education for uninsured or underinsured residents.

Key Points: 
  • TTUHSC El Paso's SuCCCeS and the Breast Cancer Education, Screening and Navigation (BEST) programs screen for cancer and provide cancer-prevention education for uninsured or underinsured residents.
  • The agency provides funding for public and private institutions of higher education and recently renewed its funding for TTUHSC El Paso's two screening programs for a total of $5 million.
  • Earlier this year, she took over as director for the Cancer Prevention and Control Division, which oversees all cancer screening programs.
  • "They see our success in El Paso and West Texas, which is a main reason why CPRIT continues funding our programs," Dr. Molokwu said.

U.S. Patent Office Completes Review of Medtronic Patents, Rejects More Axonics Challenges

Patent, 1836 U.S. Patent Office fire, PTAB, Patent Trial and Appeal Board, Inter partes review, Solution, Security (finance), Douglas v. U.S. District Court ex rel Talk America, Health, Sale, Lucia v. Securities and Exchange Commission, IPR, Patient, Electric Bond and Share Company v. Securities and Exchange Commission, Physician, Neuroscience, Hospital, IP, SNM, District court, Pain, Hearing, Technology, Safety, Intellectual property, NYSE, Central District, Pharmaceutical industry, Online gambling
Wednesday, September 22, 2021 - 8:29pm

Today's decisions complete the review process initiated by Axonics to challenge the validity of the seven total patents involved in the IP infringement case brought by Medtronic.

Key Points: 
  • Today's decisions complete the review process initiated by Axonics to challenge the validity of the seven total patents involved in the IP infringement case brought by Medtronic.
  • Medtronic is weighing its legal options with regard to the handful of invalidated patent claims in the '112 patent.
  • The '758 patent and the '148 patent expire in April 2025, the '112 patent expires in April 2024.
  • Now that the IPR is complete including the PTAB's decision in September 2020 to reject without hearing the challenge to Medtronic U.S. patent No.

Zywie® Selected as a Venture Atlanta 2021 Presenting Company

Momentum, Technology, TAG, Živa (mythology), Invesco, Consumer Technology Association, Diagnosis, Clinical, Mailchimp, FDA, Patient, Association, Physician, LinkedIn, GLOBE, Twitter, ASB, EMR, VCS, Stax, Founder, Venture, Blog, Metro Atlanta Chamber of Commerce, Wireless ambulatory ECG, Cryptocurrency, Medical device
Wednesday, September 22, 2021 - 6:46pm

ATLANTA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Zywie announced today that it has been chosen out of a record-breaking 400-plus applicants as one of the top technology companies in the Southeast to present at Venture Atlanta 2021 to be held October 20-21.

Key Points: 
  • ATLANTA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Zywie announced today that it has been chosen out of a record-breaking 400-plus applicants as one of the top technology companies in the Southeast to present at Venture Atlanta 2021 to be held October 20-21.
  • Zywie CEO and Founder, Latha Ganeshan, is very excited to be presenting at this years Venture Atlanta conference.
  • For those attending in person, Venture Atlanta is back with its always-great sessions, company presentations, networking opportunities, and outdoor dinner events.
  • The annual nonprofit event is a collaboration of the Atlanta CEO Council, Metro Atlanta Chamber, and the Technology Association of Georgia (TAG).

New Technology at Mary Bird Perkins Set to Revolutionize Cancer Treatment in Baton Rouge and Across Gulf South

Radiation, Neck, Longevity, Mary Bird Perkins Cancer Center, Neoplasm, Partnership, Louisiana State University, Program, Fontenot, BATON, Abdomen, Life expectancy, Cancer, Patient, LSU, Rectum, Physician, Head, Oncology, Growth, Adaptation, Prostate, Liver, Technology, Science, Research, Information technology, Pancreas, Foundation, Quality of life, Lung, GLOBE, Medical imaging
Wednesday, September 22, 2021 - 4:00pm

This is an absolute game-changer for Mary Bird Perkins, our patients and the state of Louisiana, said Kos Kovtun, M.D.

Key Points: 
  • This is an absolute game-changer for Mary Bird Perkins, our patients and the state of Louisiana, said Kos Kovtun, M.D.
  • The funding from Mary Bird Perkins is dedicated to the capital investment needed to enhance the facilities and clinical resources.
  • Mary Bird Perkins Cancer Center is a regional cancer care organization that has been fighting cancer for 50 years.
  • Mary Bird Perkins Cancer Foundation secures the future of cancer care by building an endowment to provide long-term sustainability ultimately advancing cancer care for generations to come.

Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform

Workflow, Surgeon, Patient, Physician, Adult, Percussion section, CEO, Trinity, European Union, Operation Time, Technology, Dissection, Union, United Kingdom, GLOBE, Medical device, Dentistry
Wednesday, September 22, 2021 - 3:44pm

Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications.

Key Points: 
  • Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications.
  • The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector.
  • Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology.
  • Weve successfully leveraged our expertise in microsurgical devices and energy delivery to create the CoolSeal portfolio, stated Robert Kline, President and CEO of Bolder Surgical.

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

Gene editing, Cancer, Royal college, Patient, University of Alberta, Development, Royal College of Physicians and Surgeons of Canada, Physician, Surgeon, Biochemistry, Head, Medicine, Glossary, University, Roivant Sciences, Clinical and Translational Science Award, Gilead Sciences, Amgen, Oncology, Safety, Internal medicine, Degenerative disease, Survival, Kite Pharma, NYSE, GLOBE, Pharmaceutical industry
Wednesday, September 22, 2021 - 3:07pm

as its Chief Medical Officer, effective September20, 2021.

Key Points: 
  • as its Chief Medical Officer, effective September20, 2021.
  • We welcome Roger and look forward to collaborating with him in working to transform the way our targeted diseases are treated.
  • Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences.
  • Previously, he held key positions at Roivant Sciences, where he was Chief Medical Officer and Executive Vice President and Head of Research and Development, Cell Design Labs, where he served as Chief Medical Officer, and Amgen, where he served as Global Product General Manager, Translational Sciences.

The National Institute on Ageing Announces New Collaboration with TELUS Health to Support Independent Living for Older Adults

Chronic pain, Efficiency, Pharmacist, NIA, Solution, Health, Social, Advisory board, Patient, Physician, National Institute on Aging, Caregiver, Apple Watch, Disability, TELUS, Risk, Technology, COVID-19, National Institute, Ryerson University, Safety, Falling, Quality of life, Telus Health, Informatics for Consumer Health, GLOBE, Residential care, Pharmaceutical industry, Medicine
Wednesday, September 22, 2021 - 3:00pm

TORONTO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Today, the National Institute on Ageing (NIA) announced a collaboration with TELUS Health to help raise public awareness about assistive technologies that can support older adults maintain active and independent lives.

Key Points: 
  • TORONTO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Today, the National Institute on Ageing (NIA) announced a collaboration with TELUS Health to help raise public awareness about assistive technologies that can support older adults maintain active and independent lives.
  • There are a growing number of tools and devices that seek to enable more independent living for older adults.
  • Our work with TELUS Health will help ensure more Canadians are better informed about technologies that can support them to live healthy lives.
  • TELUS Health delivers innovative technologies that put patients first so they can live their healthiest lives, says Juggy Sihota, vice president Consumer Health, TELUS.